peripheral artery stent
Jump to navigation
Jump to search
Indications
- stenosis or occlusion of the superficial femoral artery in patients with peripheral artery disease
Contraindications
- stenoses that cannot be dilated
- bleeding disorders
- pregnancy, breast-feeding, or planning to become pregnant within 5 years
Mechanism of action
- paclitaxel-coated stent
- dual antiplatelet therapy for life[3]
Complications
- restenosis necessitating additional therapy
- paclitaxel-coated devices (balloons & stents) associated with increased mortality (RR=1.9 at 4-5 years)[2]
More general terms
References
- ↑ FDA News Release: Nov. 15, 2012 FDA approves first drug-eluting stent to treat peripheral arterial disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327068.htm
- ↑ 2.0 2.1 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2018 Dec 18; 7:e011245 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30561254 Free Article https://www.ahajournals.org/doi/10.1161/JAHA.118.011245
- ↑ 3.0 3.1 VAMC pharmacy